Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1106-1113

  Parry, Chris M ^a,b   Kolli, Madhavi ^c   Myers, Richard E ^a   Cane, Patricia A ^a   Schiffer, Celia ^c   Pillay, Deenan ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MATRIX PROTEIN;

ALPHA HELIX; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL STRAIN HEK293; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR MODEL; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; VIRUS REPLICATION;

CELL LINE; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIGENS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; VIRUS REPLICATION;

EID: 79952327508     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01228-10     Document Type: Article

References (35)

1. Bainbridge, J. W., et al. 2001. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8:1665-1668.
2. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
3. Condra, J. H., et al. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276. (Pubitemid 26378401)
4. Condra, J. H., et al. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
5. Croteau, G., et al. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096. (Pubitemid 27030280)
6. Dam, E., et al. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345.
7. DeLano, W. L. 2002. The PyMol molecular graphics system.
8. Delaugerre, C., et al. 2009. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob. Agents Chemother. 53:2934-2939.
9. Doyon, L., et al. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769. (Pubitemid 26161824)
10. Gatanaga, H., et al. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
11. Gazzard, B. G., et al. 2008. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 9:563-608.
12. Gupta, R. K., et al. 2010. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. AIDS 24:1651-1655.
13. Hill, C. P., D. Worthylake, D. P. Bancroft, A. M. Christensen, and W. I. Sundquist. 1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. U. S. A. 93:3099-3104.
14. Holm, S. 1979. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6:65-70.
15. Jinnopat, P., et al. 2009. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01-AE strains on drug susceptibility of virus to protease inhibitors. J. Acquir. Immune. Defic. Syndr. 52:320-328.
16. Kameoka, M., et al. 2010. The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01-AE Gag in reducing viral drug susceptibility to protease inhibitors. Virology 405:129-138.
17. Larrouy, L., et al. 2010. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob. Agents Chemother. 54:2910-2919.
18. Lee, S. K., J. Harris, and R. Swanstrom. 2009. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83:8536-8543.
19. Leitner, T., et al. 2005. HIV sequence compendium 2005. Los Alamos National Laboratory, Los Alamos, NM.
20. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
21. Massiah, M. A., et al. 1994. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J. Mol. Biol. 244:198-223.
22. Molla, A., et al. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
23. Muller, B., et al. 2009. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284:29692-29703.
24. Myint, L., et al. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:444-452.
25. Naldini, L., et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
26. Nijhuis, M., et al. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
27. Nijhuis, M., et al. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36.
28. Parry, C. M., et al. 2009. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 83:9094-9101.
29. Prabu-Jeyabalan, M., E. A. Nalivaika, N. M. King, and C. A. Schiffer. 2004. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
30. Rhee, S. Y., T. F. Liu, S. P. Holmes, and R. W. Shafer. 2007. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput. Biol. 3:e87.
31. Tamiya, S., S. Mardy, M. F. Kavlick, K. Yoshimura, and H. Mistuya. 2004. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 78:12030-12040. (Pubitemid 39390787)
32. Tang, C., Y. Ndassa, and M. F. Summers. 2002. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 9:537-543.
33. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
34. Wright, E., et al. 2008. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol. 89:2204-2213.
35. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306. (Pubitemid 28175575)